ATLASKeros Therapeutics (KROS) earnings date: Nov 4, 2026
Keros Therapeutics (KROS) reports earnings for the quarter ended Sep 30, 2026 on Wed, Nov 4, 2026, after the close. Analysts expect EPS of -$0.96.
Source: company filings and exchange data · Updated Nov 2, 2026
ATLAS view on KROS
| Last price | $10.53 (-4.6%) |
|---|---|
| Normal 1-day range (±1σ) | ±2.6% |
| Earnings beat history | Beat the EPS estimate in 2 of the last 5 reports |
These figures come from the same calibrated model and valuation as the Keros Therapeutics stock page. They describe an ordinary period, not the earnings reaction itself, which is usually wider and can go either way.
Keros Therapeutics reports on Nov 4, 2026. One email the day before, with ATLAS’s read on Keros Therapeutics. You can switch it off at any time.
Alert me before KROS reportsFree to start. Creating an account takes under a minute.
Notify me when Keros Therapeutics reports
Track KROS free Add Keros Therapeutics to a free ATLAS watchlist and see its next report date in one place.
KROS earnings at a glance
| Next report (confirmed) | Wed, Nov 4, 2026 |
|---|---|
| Time | After the close |
| Period | Quarter ended Sep 30, 2026 |
| EPS estimate | -$0.96 |
| Last report | Aug 3, 2026 · Miss |
| Beat rate (last 5 reports) | 2 of 5 (40%) |
| Average EPS surprise | -17.0% |
| Average move around a report | ±3.8% (last 5) |
| Sector | Healthcare · Biotechnology |
Keros Therapeutics earnings history: last 5 reports
Keros Therapeutics last reported on Aug 3, 2026: EPS of -$1.45 against an estimate of -$1.24 (-16.9% surprise), a miss.
| Report date | EPS est. | EPS actual | Surprise | Result | Move* |
|---|---|---|---|---|---|
| Aug 3, 2026 | -$1.24 | -$1.45 | -16.9% | Miss | +1.8% |
| Jun 9, 2026 | $0.48 | $0.22 | -54.2% | Miss | -0.7% |
| May 14, 2026 | -$0.92 | -$1.21 | -31.5% | Miss | -12.4% |
| May 6, 2026 | $2.55 | $2.72 | +6.7% | Beat | -1.1% |
| Apr 20, 2026 | $0.83 | $0.92 | +10.8% | Beat | -3.1% |
*Move: change in the closing price from the last close before the report day to the close the day after it, so it captures the reaction whether the company reported before the open or after the close.
Get the full ATLAS analysis for KROS
See the fair value, the probability range and the earnings history of Keros Therapeutics on its ATLAS page.
Keros Therapeutics (KROS) stock analysisPlans from €3.99 a month.
Keros Therapeutics earnings: frequently asked questions
When does Keros Therapeutics (KROS) report earnings?
Keros Therapeutics is scheduled to report on Wednesday, November 4, 2026, after the close. ATLAS only shows a confirmed date when the company or the exchange data provides one; check the investor relations page for the call details.
What is the EPS estimate for KROS?
The consensus EPS estimate for the quarter ended Sep 30, 2026 is -$0.96 per share (USD). Estimates can change before the report.
How often does KROS beat earnings estimates?
Of its last 5 reports with a recorded result, Keros Therapeutics beat the EPS estimate 2 times; the average surprise was -17.0%. Past results do not predict the next one.
How much does KROS move around earnings?
Over its last 5 reports the stock moved an average of 3.8% (absolute, from the close before the report day to the close after it), and finished higher 1 of 5 times.
Did Keros Therapeutics beat earnings estimates last quarter?
Keros Therapeutics last reported on Aug 3, 2026: EPS of -$1.45 against an estimate of -$1.24 (-16.9% surprise), a miss.
How much does KROS usually move in a day?
On a normal trading day the ATLAS model puts KROS’s one-day range at about ±2.6%, with a 50% chance of closing higher. This is not an options-implied earnings move; earnings days are usually wider.
Also reporting on Wed, Nov 4, 2026
Educational information, not investment advice. Disclaimer